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Abstract
Background Different species of the genus Leishmania
can cause cutaneous (CL) and mucosal leishmaniasis (ML).
PCR-based tests allow a rapid diagnosis and determination
of the species, thereby enabling species-oriented treatment.
Such treatment procedures have not been evaluated to date.
Methods Patients presenting with CL and ML between
1999 and 2011 were analysed retrospectively. PCR tech-
nology was used to diagnose the disease and identify the
protozoan to the species level.
Results A total of 61 cases were reviewed, including 58
patients with CL and three patients with ML. Treatment
was effective in most patients. Treatment failure was
reported in six patients with L. panamensis (one fluco-
nazole, one ketoconazole), L. infantum (one excision, one
fluconazole), L. tropica (one paromomycin/methylben-
zethonium), L. braziliensis (1 paromomycin/methylben-
zethonium). In 11 (18 %) patients treatment had to be
interrupted due to adverse events, and in eight patients (13
%) a second treatment had to be applied. Treatment with
meglumine antimoniate had to be interrupted in six
patients, with QTc prolongation the reason for the inter-
ruption in three patients.
Conclusions Species-related, targeted treatment resulted
in good responses in CL and ML lesions. Treatment rec-
ommendations for L. panamensis were changed from
ketoconazole to miltefosine because of new evidence of
treatment failures. Meglumine antimoniate should be
restricted to species with poor response to alternative
medications and should be used with caution in patients
older than 60 years because of its toxicity. Treatment in
immunosuppressed patients was successful, but relapses
were observed when the immune system could not be
restored. This is the first report on L. aethiopica from Egypt.
Keywords Cutaneous leishmaniasis  Mucosal
leishmaniasis  Treatment  Miltefosine  Meglumine
antimoniate
Introduction
Leishmaniasis is an infection caused by intracellular pro-
tozoan parasites of the genus Leishmania and is transmitted
by various species of sand flies. The clinical manifestations
are wide and include papulo-nodular and ulcerative skin
lesions and destructive mucosal inflammation. With regard
to cutaneous leishmaniasis (CL) and mucocutaneous
leishmaniasis (ML), the parasite species are divided into
old world (OW) (Southern Europe, the Middle East, Asia,
Africa) and New World (NW) leishmaniasis (Latin
America).
Imported cases of leishmaniasis have become more
frequent in Europe over the past years due to increased
travel to risk areas. Standardised species identification and
treatment protocols are warranted to provide the patients
with the best possible treatment.
Leishmania species have different sensitivities to antile-
ishmanial drugs. The wide availability of PCR genotyping
tools allows a rapid determination of species, which is a
precondition for species-adapted treatment. National con-
sortia and international networks (Germany, France, UK,
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World Health Organization) and several authors have pub-
lished guidelines for the treatment of CL in the past decade
[1–8]. Most of these guidelines concentrate on species-ori-
ented treatment. The guidelines harmonise many issues, but
there are some differences. The recommendations are usu-
ally based on data from endemic regions, but travellers could
have different treatment response to antileishmanial drugs
than the endemic population with repeated contact to
Leishmania parasites and more treatment options.
In this report, we summarize the clinical experiences of
61 travellers with CL or ML who were treated with spe-
cies-oriented therapy.
Patients and methods
This study was a retrospective analysis of patients with CL
or ML diagnosed by PCR-based tests from January 1999 to
December 2011 at the Swiss Tropical and Public Health
Institute (Swiss TPH). The study cohort comprised 61
patients who met these criteria. The following data were
extracted from the medical records: age, sex, endemic
region(s) visited, dates of visit in endemic regions, number,
size and site of the lesion(s), results of PCR-based test
regarding species specification and treatment modalities
(effectiveness, adverse events).
Patients were mostly treated according to the recom-
mendations published between 1994 and 2009 [1–3] and
followed-up by the Swiss TPH, hospitals or their general
physicians.
The clinical cure of the lesion was defined as complete
re-epithelialization or/and flattening of papules and nodules
before day 90 after treatment initiation. Relapses were
defined by the appearance of new lesions after clinical cure
within 12 months.
DNA extraction and PCR amplification of the poly-
morphic miniexon marker was performed as described
previously [9, 10]. The amplicon size was indicative of
Leishmania species complexes. For species determination,
PCR products were digested with four to six restriction
enzymes depending on the complex identified, and the
restriction fragments were separated by polyacrylamide gel
electrophoresis; the patterns of restriction fragments were
then compared to those from reference strains [9].
Ethical considerations in line with those of the ‘Ethi-
kkommission beider Basel’ (EKBB) (3rd October 2011)
and the ‘Commission cantonale (VD) d’e´thique de la
recherche sur l’eˆtre humain’ (20th April 2012). Only
patients with signed informed consent were included.
Results
Patients and description of the lesions
Between January 1999 and December 2011 CL was diag-
nosed in 58 patients and ML in three patients. Of the 61
patients, 23 (38 %) were female and 38 (62 %) were male,
and age at the time of diagnosis ranged from 1 to 86
(median 34.5) years (Table 1). The clinical features, such
as number of lesions and size of lesion, are summarized in
Table 1. In patients with CL, the lesions were localized on
the arms (n = 21; 30 %), legs (n = 21; 30 %), head
(n = 14; 20 %) and trunk (n = 14; 20 %). One immuno-
suppressed patient presented with disseminated CL (see
below). In the three patients with ML, the lesions were
localized on the mouth (n = 2; L. infantum) and in the nose
(n = 1; L. braziliensis).
The most likely country of acquisition of the infection
and the involved species are described in Table 2.
Treatment
The species-specific treatment response is described in
Table 3. In 11/61 (18 %) patients treatment had to be
interrupted due to adverse event(s); in eight (13 %) patients
a second treatment had to be applied.
Systemic meglumine antimoniate treatment had to be
interrupted in 6/18 (33 %) patients due to adverse event(s) and
could not be resumed in the following five patients:
– 73-year-old patient: QTc prolongation and elevated
liver enzymes [11];
– 64-year-old patient: skin eruption, hypokalaemia
(2.3 mmol/l) and QTc prolongation (600 ms);
Table 1 Description of the
total patient cohort (n = 61)
and aspects of skin lesions
(n = 57)
CL Cutaneous leishmaniasis,
ML mucocutaneous
leishmaniasis
a Number of patients for whom
data were not available
Patients/description of lesions Old World cases (n = 36) New World cases (n = 25) All cases
Gender, (n) male/female 19/17 19/6 38/23
Age (years), median (range) 43 (1–86) 31 (9–71) 34.5 (1–86)
CL/ML (n) 34/2 24/1 58/3
Number of lesions, mean (range) 2.9 (1–13) (10a) 2 (1–6) (4a) 2.5 (1–13)
(14a)
Solitary/multiple, ( n) 10/17 (9a) 12/9 (4a) 22/26 (13a)
Size of lesion (cm), mean (range) 2.6 (1–6) (13a) 3.2 (1–6) (9a) 2.9 (1–6)
(22a)
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– 44-year-old patient: skin reaction, myalgia, QTc pro-
longation (513 ms);
– 49-year-old patient: skin reaction;
– 32-year-old patient: local reaction.
In the sixth patient (aged 44 years) who had elevated
liver enzymes, treatment was resumed after 3 days.
Pentamidine treatment had to be interrupted in 2/6
patients and could not be resumed in both cases:
– 32-year-old patient: anaphylactic shock;
– 61-year-old patient: aseptic abscess at injection site.
Table 3 Response of treatment according to species
Leishmania species Treatment Successful No
response
Relapse
Old World (n = 36)
L. major (n = 17) Fluconazole/
ketoconazole
10 0 0
Leishcutana 3 0 0
Antimonials 1 0 0
Cryo-/
thermotherapy
3 0 0
L. infantum/
donovani (n = 14)
Miltefosine 4 (19b) 0 0
Antimonials 3 (19b) 0 0
Leishcutana 2 0 0
Amphotericin B 3 (29b) 0 0
Fluconazole 0 1 0
Cryo-/
thermotherapy
5 0 1
L. tropica (n = 4) Fluconazole 2 0 0
Itraconazole/
cryotherapy
1 0 0
Infiltration with
antimonials
1 0 0
Leishcutana 0 1 0
L. aethiopica
(n = 1)
Miltefosine 1 0 0
New World (n = 25)
L. braziliensis
(n = 8)
Antimonials 6 0 1
Amphotericin B 1 0 0
Pentamidine 1 0 0
Leishcutana 0 1 0
L. guyanensis
(n = 6)
Pentamidine 4 0 0
Antimonials 1 0 0
Infiltration with
antimonials
1 0 0
L. panamensis
(n = 5)
Miltefosine 2 0 0
Ketoconazole 2 1 0
Fluconazole 0 1 0
Antimonials 1 0 0
L. peruviana
(n = 3)
Antimonials 3 0 0
L. mexicana
(n = 1)
Spontaneous
disappearance
1 0 0
L. naiffi (n = 1) Leishcutana 1 0 0
L. chagasi (n = 1) Amphotericin B 1 0 0
a Leishcutan: 15 % paromomycin and 12 % methylbenzethonium ointment
b Same patient with Good syndrome, mucosal leishmaniasis and 3 relapses
treated with miltefosine 19, antimonials 19, amphotericin B 29; (for details
see text)
Table 2 Country of acquisition of leishmaniasis and Leishmania
species involveda
Country of acquisition Number/species
Old World (n = 27)
Europe
Macedonia 1 L. infantum
France 1 L. infantum
Sicily 1 L. infantum
Middle East
Israel 1 L. infantum,
1 L. major
Syria 1 L. tropica
North Africa
Morocco 3 L. infantum,
4 L. major
Egypt 1 L. aethiopica
Tunisia 1 L. major
Algeria 1 L. donovani
Sudan 1 L. major
Canaries 1 L. infantum
Sub-Saharan Africa
Burkina Faso 5 L. major
Chad 1 L. major
Kenya 1 L. major
Senegal 1 L. major
South Asia
Afghanistan 1 L. tropica
New world (n = 22)
Central America
Costa Rica 4 L. panamensis
Guatemala 1 L. mexicana
Panama 1 L. panamensis
South America
Ecuador 3 L. braziliensis,
1 L. peruviana
Bolivia 3 L. braziliensis,
1 L. peruviana
Guyana 5 L. guyanensis
Brazil 1 L. naiffi
1 L. chagasi
Peru 1 L. peruviana
a Data were available for 49 patients; for 12 patients no data were
available
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Miltefosine treatment had to be interrupted in 1/7
patients and could be resumed [11]:
– 64-year-old patient with vomiting and disturbances of
kidney function (creatinine 160 lmol/l) and hypokal-
aemia (2.5 mmol/l). After oral rehydration treatment
could successfully be completed.
Local treatment consisted of paromomycin 15 %/meth-
zylbenzethonium 12 % (Leishcutan) and intralesional
meglumine antimoniate, respectively. Treatment was
interrupted in 1/8 patients (Leishcutan) and 1/4 patients
(meglumine antimoniate) due to strong local reactions.
Pregnancy
Three CL patients were in their last trimester of pregnancy
at the time of diagnosis: one patient was treated with
excision of the lesion twice, one patient showed sponta-
neous cure of the lesions after delivery and one patient was
treated with fluconazole 200 mg/day for 6 weeks. All
children were born healthy.
Immunusuppression
Three patients were treated in the context of relevant
immunosuppression:
– A mucosal leishmaniasis due to L. infantum in a patient
with Good syndrome responded well to treatment with
meglumine antimoniate. Three relapses after 2–3 years
responded well to amphotericin B (29) and miltefosine
(19).
– A patient with rheumatoid arthritis developed dissem-
inated CL after the dose of a tumour necrosis factor-
alpha (TNF-a) inhibitor had been increased. Treatment
with the TNF-a inhibitor was discontinued and the
lesions healed under treatment with meglumine anti-
moniate. Treatment with the TNF-a inhibitor could be
restarted at a lower dosage without relapse of CL.
– A patient with ankylosing spondylitis (Bechterew’s
disease) developed multiple lesions at both auricles
(ears) under treatment with etanercept 50 mg/week.
Treatment with the TNF-a inhibitor was stopped. The
lesions healed under treatment with miltefosine. Treat-
ment with the TNF-a inhibitor could be restarted at a
lower dosage without relapse of CL.
Discussion
Species-oriented treatment has been established in travel-
lers [1–3, 5, 6] for more than one decade following the
increased availability of PCR-based diagnostic techniques.
However, the large number of different species in a rela-
tively low number of patients with CL or ML does not
allow a comprehensive evaluation of the proposed recom-
mendations. Only a multicentre survey study will provide
sufficient power to draw conclusions on treatment outcome
of different species. Such a study has recently been started
and will last for several years in order to collect data on
adequate numbers of patients. Here, we present our limited
experiences with species-oriented treatment.
The cases presented here cover a wide variety of CL
species originating from 24 countries, mainly from Latin
America and the Mediterranean region, and less frequently
from Sub-Saharan Africa and South Asia. Since more than
one species is endemic in most countries, PCR-based
techniques are needed for species determination. The spe-
cies reported in our study are endemic in the visited
countries with one exception: L. aethiopica was detected in
a patient who has never travelled to a country endemic for
L. aethiopica [12]. The most likely country of acquisition is
Egypt, but this individual had also travelled to Namibia,
South Africa, Zimbabwe, and Southern France.
Systemic treatment was administered to patients with
New World leishmaniasis (except L. mexicana), ML,
established metastatic spread to lymphnodes, localisation
in the face (nose, eyelids) or close to joints, multiple or
large lesions or those with no response to topical treatment.
However a recent analysis of the available literature
revealed that local treatment might be considered as a
valuable treatment option for travellers suffering from NW
CL provided that there are no risk factors for developing
ML, such as multiple lesions, large lesions ([4 cm2),
localisation of the lesion on the head or neck, immuno-
suppression or acquisition of infection in Bolivia [13].
The cure rates of L. major were excellent with local and
systemic treatment. The only treatment failure was
observed in a case where toxicity of meglumine antimo-
niate demanded treatment cessation. However, these good
results have to be compared to high spontaneous cure rates
of 53 % at 8 weeks [14], from 40 to 70 % at 3 months and
close to 100 % at 12 months [15]. For small lesions, simple
wound care and observation should be an option, and the
use of the toxic systemic meglumine antimoniate should be
restricted to lesions for which other treatments have failed.
Little data have been published on the treatment of L.
infantum lesions. We found that local treatment was
effective in most cases and that miltefosine or liposomal
amphotericin B were effacious treatment options in cases
where systemic treatment was indicated.
Local treatment and fluconazole was effective in four
patients with CL due to L. tropica. According to recent data
cryotherapy combined with intralesional antimonials pro-
duces excellent cure rates in CL due to L. major and L.
tropica, and this treatment combination should be the first-
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line treatment for local therapy [16–18]. The spontaneous
cure rates of CL due to L. tropica are considerable lower
than those observed in CL due to L. major, reaching 1 % at
3 months, 68 % at 12 months [15] and usually close to
100 % in 6 months to 3 years.
Systemic meglumine antimoniate has been the first-line
treatment for leishmaniasis caused by L. braziliensis for
decades and was successfully used in the patients included
in our study. Local treatment should only be applied when
the above-mentioned exclusion criteria are taken into
account [13].
Pentamidine is widely used to treat CL due to L. gu-
yanensis, and all patients included in our study who
received pentamidine were cured. If pentamidine is con-
traindicated, miltefosine is a possible alternative [19].
In previous recommendations ketoconazole was the
treatment of first choice for L. panamensis lesions due to its
low toxicity and cost. However, treatment guidelines were
changed due to a number of developments. Firstly, there
have been new publications on miltefosine showing that
the cure rates with miltefosine are superior to placebo (91
vs. 38 %, respectively) [20] and similar to (60 vs. 72 %)
[21] or higher than (92 vs. 63 %) [22] those obtained using
pentavalent antimonials. Secondly, a critical analysis of the
existing literature revealed that the previous recommen-
dations on the use of ketoconazole were based on only one
study with a limited number of patients (n = 9) and a cure
rate of 76 % [23]. Thirdly, experiences in the reported
collective: ketoconazole only cured 2/4 patients, but mil-
tefosine achieved a cure in two patients during the study
period and in an additional four patients during the post-
study period.
Due to adverse events, treatment had to be interrupted in
18 % of the cases, and an alternative treatment had to be
applied in 13 % of patients. Meglumine antimoniate was
responsible for the most dangerous adverse events,
including QTc prolongation and severe hypokaliaemia
(3 patients). These adverse events highlight the need to
perform electrocardiography (ECG) and electrolyte con-
trols once to twice per week. Of note is that the average age
of these three patients was 60 years, which is much higher
than the average age of 33 years in patients without rele-
vant QTc prolongation. Because of its toxicity, meglumine
antimoniate should only be used in cases where it is
superior to alternative therapy (e.g. against L. braziliensis)
or after alternative treatments have failed. In elderly
patients ([60–65 years) meglumine antimoniate should be
used with caution: ECG, kidney function, electrolytes, liver
tests and haematological parameters need to be followed up
twice weekly) [24].
It is notable that treatment with pentamidine had to be
interrupted in two patients because of an anaphylactic
reaction in one patient and an aseptic abscess at the
injection sites in another patient. Therefore, we propose
that pentamidine be administered as an intravenous
infusion and not as an intramuscular injection. The par-
omomycin/methylbenzethonium ointment led to interrup-
tion of treatment due to a strong local inflammation, but
treatment could be resumed and the lesion was cured.
Our case of the patient with Good syndrome demon-
strated that relapses have to be expected if restoration of
the immune system is not achieved. The increasing number
of patients treated with immune-modulating drugs is
associated with the risk of developing CL and ML. As the
exposure often dated back many months or even years and
the initially treating physicians were often not familiar with
the clinical presentation, diagnosis of CL was delayed in
some of the patients described here.
In both patients with rheumatoid diseases, treatment
with the TNF-a inhibitor was stopped during antileishma-
nial treatment but was resumed (at a lower dosage) after
successful cure of the skin lesions. No relapse was
observed after treatment with anti-TNF-a inhibitor therapy
was resumed.
The limitations of this study include the small number of
patients and the fact that not all patients were treated
according to our recommendations. Some recommenda-
tions have been changed due to new evidence. A further
reason for the different treatment approach to some species
(mainly L. infantum) is the lack of published evidence and
the variable availability of some treatments.
Conclusions
Species-specific treatment showed good results in CL and
ML lesions. L. panamensis treatment recommendations
were changed from ketoconazole to miltefosine because of
recent publications on miltefosine, a critical review of
ketoconazole and the observed treatment failures. Meglu-
mine antimoniate should be restricted to species which
respond poorly to alternative medications. The drug should
be used with caution in patients older than 60 years
because of its toxicity. Treatment in immunosuppressed
patients was successful, but relapses were observed when
the immune system could not be restored. This is the first
report on L. aethiopica from Egypt.
Conflict of interest We declare that there is no conflict of interests.
References
1. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of
cutaneous leishmaniasis among travellers. J Antimicrob Chemo-
ther. 2004;53:158–66.
Cutaneous leishmaniasis in Switzerland 1181
123
2. Blum JA, Hatz CF. Treatment of cutaneous leishmaniasis in
travelers 2009. J Travel Med. 2009;16:123–31.
3. Blum J, Hatz C, Junghanss T. The therapy of cutaneous and
mucocutaneous leishmaniasis. Dtsch Med Wochenschr. 1994;
119:1169–72.
4. Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis
in travellers. Lancet Infect Dis. 2006;6:342–9.
5. Boecken G, Sunderkotter C, Bogdan C, et al. Diagnosis and
therapy of cutaneous and mucocutaneous leishmaniasis in Ger-
many. J Dtsch Dermatol Ges. 2011;9:1–51.
6. Mitropoulos P, Konidas P, Durkin-Konidas M. New World
cutaneous leishmaniasis: updated review of current and future
diagnosis and treatment. J Am Acad Dermatol. 2010;63:309–22.
7. Goto H, Lindoso JA. Current diagnosis and treatment of cuta-
neous and mucocutaneous leishmaniasis. Expert Rev Anti Infect
Ther. 2010;8:419–33.
8. Buffet PA, Rosenthal E, Gangneux JP, et al. Therapy of leish-
maniasis in France: consensus on proposed guidelines. Presse
Med. 2011;40:173–84.
9. Marfurt J, Niederwieser I, Makia D, Beck H-P, Felger I. Diag-
nostic genotyping of Old and New World Leishmania species by
PCR-RFLP. Diagn Microbiol Infect Dis. 2003;46:115–24.
10. Marfurt J, Nasereddin A, Niederwieser I, Jaffe CL, Beck HP,
Felger I. Identification and differentiation of Leishmania species
in clinical samples by PCR amplification of the miniexon
sequence and subsequent restriction fragment length polymor-
phism analysis. J Clin Microbiol. 2003;41:3147–53.
11. Neumayr ALC, Walter C, Stoeckle M, Braendle N, Glatz K,
Blum JA. Successful treatment of imported mucosal Leishmania
infantum leishmaniasis with miltefosine after severe hypokalemia
under meglumine antimoniate treatment. J Travel Med. 2012;19:
124–6.
12. Pratlong F, Dereure J, Ravel C, et al. Geographical distribution
and epidemiological features of Old World cutaneous leishman-
iasis foci, based on the isoenzyme analysis of 1048 strains. Trop
Med Int Health. 2009;14:1071–85.
13. Blum J, Lockwood DNJ, Visser L, et al. Local or systemic
treatment for new world cutaneous leishmaniasis? Re-evaluating
the evidence for the risk of mucosal leishmaniasis. Int Health.
2012;4:153–63.
14. Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A random-
ized, double-blind, placebo-controlled clinical trial of itraconaz-
ole in the treatment of cutaneous leishmaniasis. J Eur Acad
Dermatol Venereol. 2005;19:80–3.
15. Bailey MS, Lockwood DN. Cutaneous leishmaniasis. Clin Der-
matol. 2007;25:203–11.
16. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative
study of the efficacy of combined cryotherapy and intralesional
meglumine antimoniate (Glucantime) vs. cryotherapy and int-
ralesional meglumine antimoniate (Glucantime) alone for the
treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43:
281–3.
17. Eldarouti MA, Alrubaie SM. Cutaneous leishmaniasis—treat-
ment with combined cryotherapy and intralesional stibogluconate
injection. Int J Dermatol. 1990;29:56–9.
18. Salmanpour R, Razmavar MR, Abtahi N. Comparison of int-
ralesional meglumine antimoniate, cryotherapy and their combi-
nation in the treatment of cutaneous leishmaniasis. Int J
Dermatol. 2006;45:1115–6.
19. Chrusciak-Talhari A, Dietze R, Chrusciak TC, et al. Randomized
controlled clinical trial to access efficacy and safety of miltefo-
sine in the treatment of cutaneous leishmaniasis caused by
Leishmania (Viannia) guyanensis in Manaus. Brazil. Am J Trop
Med Hyg. 2011;84:255–60.
20. Soto J, Arana A, Toledo J, et al. Miltefosine for new world
cutaneous leishmaniasis. Clin Infect Dis. 2004;38:1266–72.
21. Velez I, Lopez L, Sanchez X, Mestra L, Rojas C, Rodriguez E.
Efficacy of miltefosine for the treatment of American cutaneous
leishmaniasis. Am J Trop Med Hyg. 2010;83:351–6.
22. Rubiano LC, Miranda MC, Arenas SM, et al. Noninferiority of
miltefosine versus meglumine antimoniate for cutaneous leish-
maniasis in children. J Infect Dis. 2012;205:684–92.
23. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against
Leishmania braziliensis panamensis cutaneous leishmaniasis. Am
J Med. 1990;89:147–55.
24. Wise ES, Armstrong MS, Watson J, Lockwood DN. Monitoring
toxicity associated with parenteral sodium stibogluconate in the
day-case management of returned travellers with new world
cutaneous leishmaniasi. PLoS Negl Trop Dis. 2012;6:e1688.
1182 V. Mosimann et al.
123
